CYK Partner Sam Roberts writes for Investment Monitor on the difficulties of investing in medtech as highlighted by the recent guilty verdict reached in the Theranos trial. See link here for full article.
Fix a time to discuss
Schedule a no-obligation 15 minute call with one of our lawyers to discuss your issue.
Contact the author of this article directly
If you have a question or comment about this article, we'd like to hear from you.
